VanEck Pharmaceutical ETF $PPH is Adamsbrown Wealth Consultants LLC’s 7th Largest Position

Adamsbrown Wealth Consultants LLC raised its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 143,045 shares of the company’s stock after acquiring an additional 6,146 shares during the quarter. VanEck Pharmaceutical ETF makes up approximately 4.1% of Adamsbrown Wealth Consultants LLC’s holdings, making the stock its 7th largest position. Adamsbrown Wealth Consultants LLC owned 1.24% of VanEck Pharmaceutical ETF worth $14,758,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Citigroup Inc. grew its stake in shares of VanEck Pharmaceutical ETF by 987.8% in the 3rd quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock worth $64,896,000 after buying an additional 652,175 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in VanEck Pharmaceutical ETF by 2,852.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock worth $22,503,000 after buying an additional 247,171 shares in the last quarter. Revere Asset Management Inc purchased a new position in shares of VanEck Pharmaceutical ETF during the third quarter valued at approximately $15,628,000. Qube Research & Technologies Ltd lifted its holdings in shares of VanEck Pharmaceutical ETF by 368.5% during the 3rd quarter. Qube Research & Technologies Ltd now owns 75,844 shares of the company’s stock valued at $6,853,000 after buying an additional 59,654 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in VanEck Pharmaceutical ETF by 346,140.0% in the second quarter. Tower Research Capital LLC TRC now owns 34,624 shares of the company’s stock valued at $3,046,000 after acquiring an additional 34,614 shares during the period.

VanEck Pharmaceutical ETF Trading Down 0.7%

Shares of NASDAQ PPH opened at $101.96 on Friday. VanEck Pharmaceutical ETF has a 12-month low of $77.67 and a 12-month high of $112.58. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of 20.21 and a beta of 0.54. The firm has a 50 day moving average of $107.13 and a 200 day moving average of $100.34.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.